27855-25-0

Basic information

• Product Name: (1,3-BENZODIOXOL-5-YLCARBONYL)AMINO]ACETIC ACID
• Synonyms: Hippuricacid, 3,4-(methylenedioxy)- (6CI,8CI); 3,4-Methylenedioxybenzoylglycine;3,4-Methylenedioxyhippuric acid; Piperonylglycine;[(3,4-Methylenedioxybenzoyl)amino]acetic acid
• CAS NO: 27855-25-0
• Molecular Formula: C₁₀H₉NO₅
• Molecular Weight: 223.183
• Mol File: 27855-25-0.mol

Chemical Properties

• Boiling Point: 447.7°Cat760mmHg
• Flash Point: 224.6°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 8.43E-09mmHg at 25°C
• CAS DataBase Reference: (1,3-BENZODIOXOL-5-YLCARBONYL)AMINO]ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (1,3-BENZODIOXOL-5-YLCARBONYL)AMINO]ACETIC ACID(27855-25-0)
• EPA Substance Registry System: (1,3-BENZODIOXOL-5-YLCARBONYL)AMINO]ACETIC ACID(27855-25-0)

Safety Data

• Hazardous Substances Data: 27855-25-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H9NO5/c12-9(13)4-11-10(14)6-1-2-7-8(3-6)16-5-15-7/h1-3H,4-5H2,(H,11,14)(H,12,13)/p-1

Upstream product

• 25054-53-9 3,4-(methylenedioxy)benzoyl chloride 
• 56-40-6 glycine 
• 76208-96-3 ethyl 2-(benzo[d][1,3]dioxole-5-carboxamido)acetate 
• 120-57-0 piperonal 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 94-53-1 Piperonylic acid 

Downstream Products

• 94-53-1 Piperonylic acid 
• 56-40-6 glycine 
• 851688-33-0 N-piperonyloyl-glycine-(3,4-dimethoxy-phenethylamide) 
• 132311-57-0 N-<(phenylamino)carbonylmethyl>-3,4-methylenedioxybenzamide 
• 132362-64-2 Benzo[1,3]dioxole-5-carboxylic acid (p-tolylcarbamoyl-methyl)-amide 
• 132311-58-1 Benzo[1,3]dioxole-5-carboxylic acid [(2,4-dichloro-phenylcarbamoyl)-methyl]-amide 
• 19500-46-0 3,3'-[4-(2-benzo[1,3]dioxol-5-yl-5-oxo-oxazol-4-ylidenemethyl)-phenylazanediyl]-bis-propionitrile 
• 109700-75-6 2-benzo[1,3]dioxol-5-yl-4-(4-dimethylamino-benzylidene)-4H-oxazol-5-one 

Relevant articles and documents

Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies

Fungal infections have become a serious medical problem due to the high infection rate and the frequent emergence of drug resistance. Ergosterol is an important structural component of the fungal cell membrane, its synthetases (squalene epoxidase (SE) and 14α-demethylase (CYP51)) are considered as the key points to block the ergosterol synthesis. In this study, we designed a series of dual-target arylamides derivatives based on the analysis of active sites (SE, CYP51). Subsequently, these target compounds were synthesized, and their antifungal activity was evaluated. Most of compounds demonstrate the potent antifungal activity against multiple Candida spp. and A. fum. In particular, the antifungal activities of compounds 10b and 11c are not only superior to positive control drugs, but also have significant inhibitory effects on drug-resistant fungi (C.alb. Strain100, C.alb. Strain103). Therefore, their action mechanism was further studied. Cellular uptake and electron microscopy observation showed that target compounds were able to enter fungal cytoplasmic region through free diffusion, and destroyed cell membrane structure. At the same time, preliminary mechanisms have demonstrated that they can affect the synthesis of ergosterol by inhibiting the activity of dual targets. It is worth noting that they also can exhibit excellent antifungal activity and low toxic side effects in vivo. Their ADMET properties and binding models were established will be useful for further lead optimization.

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinophathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.